Immix Biopharma, Inc. IMMX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -74.4%+37.0pp | -54.9%+90.8pp | -182.5%-65.2pp | -162%-59.5pp | -111.4%-19.7pp | |
| Return on assets | -60.4%+16.7pp | -46%+54.8pp | -104.2%-12.3pp | -104%-18.3pp | -77.1%-0.5pp | |
| Liquidity | ||||||
| Current ratio | 8.8×+7.0× | 10×+7.7× | 1.5×-1.9× | 1.2×-5.8× | 1.8×-4.0× | |
| Quick ratio | 8.8×+7.0× | 10×+7.7× | 1.5×-1.9× | 1.2×-5.8× | 1.8×-4.0× | |
| Cash ratio | 7.5×+5.8× | 9.3×+7.3× | 1.5×-1.5× | 1.2×-5.0× | 1.7×-3.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0×-0.1× | 0.1×— | 0.2×— | 0.1×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×— | 0.1×— | 0.1×— | |
| Per Share | ||||||
| Book value per share | $1.52+372% | $2.85+507% | $0.26-56.6% | $0.16-81.3% | $0.32-72.9% | |
| Valuation | ||||||
| Market capitalization | $691.97M+1,008% | $275.6M+355% | $68.27M+55.7% | $62.45M+9.6% | $46.57M-35.3% | |
| Enterprise value | $613.75M+1,190% | $182.74M+316% | $53.43M— | $51.85M— | $31.71M— | |
| Price / book | 8.2×+1.7× | 2.9×-1.6× | 8.3×+5.8× | 13.4×+11.0× | 4.9×+2.3× | |
| Free cash flow yield | -4.7%+16.7pp | -8.9%— | -22.6%— | -21.6%— | —— | |
| Earnings yield | -5%+28.4pp | -10.7%+25.0pp | -34.5%+15.4pp | -37%-3.7pp | -44.9%-19.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immix Biopharma, Inc.'s ratios come from?
- Every ratio is computed from Immix Biopharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.